ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

  • P-ISSN2233-4203
  • E-ISSN2093-8950
  • ESCI, SCOPUS, KCI

논문 상세

Home > 논문 상세
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

A Sensitive and Rapid LC-MS/MS Method for Determination of Berberine in Human Plasma

Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2019, v.10 no.2, pp.56-60
https://doi.org/10.5478/MSL.2019.10.2.56
Jae Hee Kim (Kangwon National University)
Xuan-Lan Mai (Kangwon National University)
Kyu Yeon Kim (Caleb Multilab Inc.)
Min-Seok Sim (Kangwon National University)
So-Yeon Lee (Kangwon National University)
Hee-Won Seo (Kangwon National University)
Gunhee Lee (Kangwon National University)
Dae Jung Kim (Kangwon National University)
Kyeong Ho Kim (Kangwon National University)
  • 다운로드 수
  • 조회수

Abstract

Coptidis Rhizoma (CR) has been used widely in traditional medicine to treat common diseases. This study aimed to develop a high-sensitivity liquid chromatography-tandem mass (LC-MS) spectrometry method for the evaluation of the pharmacokinetics of a new natural product that contain CR extract with the main bioactive compound, berberine, at trace concentrations. Human plasma samples were pretreated with methanol by a protein precipitation method. Berberine was analyzed on a Kinetex C18 column (2.1 mm × 50 mm, 100 Å, 1.7 µm) using a mobile phase of 10 mM ammonium formate/0.1% formic acid in water (A) and acetonitrile (B) (50:50, v/v) with a flow rate of 0.25 mL/min. The analyte was detected by using electrospray ionization in positive mode with multiple reaction monitoring (MRM). The method was sensitive, with a lower limit of quantification of 1 pg/mL, which has not been previously obtained. The method was validated (over the range of 1–50 pg/mL) and applied successfully for the pharmacokinetic study of human plasma samples.

keywords
Coptidis Rhizoma, berberine, human plasma, LC-MS/MS, pharmacokinetic study


참고문헌

1

Benzie, I. F. F. (2011). Biomolecular and Clinical Aspects:Taylor &Francis Group.

2

Neelesh, S. (2014). . J Molecules, 19, 14567-.

3

Pharmacopoeia Commission of the People's Republic of China. Pharmacopoeia of the People's Republic of China.

4

Hu, J. P. (2000). . Oral Dis, 6, 297-.

5

Tang, J. (2009). . Ethnopharmacol, 126, 5-.

6

Chin, L. W. (2010). . Arch. Virol, 155, 1933-.

7

이병훈. (2017). Coptidis Rhizoma extract inhibits replication of respiratory syncytial virus in vitro and in vivo by inducing antiviral state. The Journal of Microbiology, 55(6), 488-498.

8

Meng, F. C. (2018). . Chin. Med, 13, 13-.

9

Deng, Y. (2008). . J. Chromatogr. B, 863, 195-.

10

Feng, J. (2010). . J. Pharm. Biomed. Anal, 53, 591-.

11

Liu, M. (2015). . J. Chromatogr. B, 1006, 8-.

12

Li, X. (2009). . Chromatographia, 70, 1113-.

13

World Medical Association. (2013). . JAMA, 310, 2191-.

14

Hutchinson, D.R. ICH GCP guidelines: indexed pocketbook: ICH harmonised tripartite guideline:guideline for good clinical practice E6 (R1).

15

Korea Food and Drug Administration. Korea good clinical practice (KGCP) guidelines.

16

U.S Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation.

투고일Submission Date
2019-04-18
수정일Revised Date
2019-06-07
게재확정일Accepted Date
2019-06-13
상단으로 이동

Mass Spectrometry Letters